| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 84 | 2020 | 232 | 21.610 |
Why?
|
| Nucleus Accumbens | 40 | 2020 | 94 | 11.590 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 40 | 2017 | 97 | 9.070 |
Why?
|
| Ethanol | 25 | 2018 | 186 | 8.650 |
Why?
|
| Cocaine | 38 | 2019 | 256 | 8.490 |
Why?
|
| Dopamine Uptake Inhibitors | 24 | 2019 | 117 | 7.200 |
Why?
|
| Presynaptic Terminals | 14 | 2018 | 37 | 5.280 |
Why?
|
| Amphetamine | 15 | 2019 | 37 | 4.260 |
Why?
|
| Central Nervous System Stimulants | 14 | 2019 | 75 | 4.190 |
Why?
|
| Central Nervous System Depressants | 12 | 2017 | 63 | 4.140 |
Why?
|
| Self Administration | 32 | 2019 | 297 | 3.920 |
Why?
|
| Animals | 103 | 2020 | 7450 | 3.800 |
Why?
|
| Cocaine-Related Disorders | 12 | 2019 | 99 | 3.220 |
Why?
|
| Alcohol Drinking | 10 | 2018 | 247 | 3.100 |
Why?
|
| Receptors, Opioid, kappa | 7 | 2017 | 24 | 3.010 |
Why?
|
| Mice, Inbred C57BL | 35 | 2017 | 766 | 2.690 |
Why?
|
| Corpus Striatum | 10 | 2019 | 60 | 2.680 |
Why?
|
| Rats | 39 | 2019 | 1586 | 2.680 |
Why?
|
| Social Isolation | 6 | 2018 | 43 | 2.650 |
Why?
|
| Mice | 49 | 2018 | 2476 | 2.580 |
Why?
|
| Rats, Sprague-Dawley | 34 | 2019 | 738 | 2.520 |
Why?
|
| Methylphenidate | 8 | 2015 | 36 | 2.450 |
Why?
|
| Synaptic Transmission | 13 | 2017 | 116 | 2.400 |
Why?
|
| Ventral Tegmental Area | 11 | 2018 | 31 | 2.060 |
Why?
|
| Brain | 15 | 2016 | 949 | 2.010 |
Why?
|
| Alcoholism | 6 | 2018 | 101 | 1.970 |
Why?
|
| Receptors, Dopamine D2 | 16 | 2016 | 79 | 1.960 |
Why?
|
| Male | 75 | 2018 | 19091 | 1.960 |
Why?
|
| Motor Activity | 16 | 2018 | 325 | 1.940 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2016 | 629 | 1.800 |
Why?
|
| Behavior, Animal | 13 | 2016 | 250 | 1.720 |
Why?
|
| Signal Transduction | 9 | 2017 | 687 | 1.460 |
Why?
|
| Drug Tolerance | 8 | 2019 | 32 | 1.440 |
Why?
|
| Electrochemical Techniques | 7 | 2014 | 23 | 1.270 |
Why?
|
| Neostriatum | 4 | 2014 | 22 | 1.260 |
Why?
|
| Serotonin | 5 | 2015 | 37 | 1.220 |
Why?
|
| Autoreceptors | 3 | 2016 | 9 | 1.210 |
Why?
|
| Norepinephrine | 4 | 2018 | 77 | 1.130 |
Why?
|
| Caudate Nucleus | 6 | 2015 | 25 | 1.130 |
Why?
|
| Electric Stimulation | 10 | 2016 | 104 | 1.120 |
Why?
|
| Nerve Tissue Proteins | 8 | 2015 | 120 | 1.020 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2016 | 59 | 1.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 6 | 2016 | 23 | 0.950 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 493 | 0.920 |
Why?
|
| Mice, Knockout | 17 | 2016 | 444 | 0.880 |
Why?
|
| Extracellular Space | 6 | 2015 | 25 | 0.870 |
Why?
|
| Microdialysis | 11 | 2015 | 34 | 0.840 |
Why?
|
| Membrane Transport Proteins | 6 | 2004 | 34 | 0.830 |
Why?
|
| Motivation | 4 | 2017 | 111 | 0.820 |
Why?
|
| Piperidines | 4 | 2016 | 117 | 0.800 |
Why?
|
| Neurons | 5 | 2015 | 409 | 0.760 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 2 | 2016 | 8 | 0.750 |
Why?
|
| Electrochemistry | 8 | 2017 | 14 | 0.730 |
Why?
|
| Neuropeptides | 2 | 2010 | 17 | 0.720 |
Why?
|
| Time Factors | 12 | 2015 | 2146 | 0.720 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 73 | 0.710 |
Why?
|
| Stress, Psychological | 2 | 2018 | 218 | 0.700 |
Why?
|
| Putamen | 5 | 2019 | 25 | 0.680 |
Why?
|
| Narcotic Antagonists | 2 | 2016 | 39 | 0.680 |
Why?
|
| Reward | 7 | 2020 | 64 | 0.680 |
Why?
|
| Histamine H1 Antagonists | 2 | 2012 | 9 | 0.660 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2018 | 5 | 0.650 |
Why?
|
| Rats, Long-Evans | 5 | 2018 | 72 | 0.640 |
Why?
|
| Neuronal Plasticity | 2 | 2016 | 80 | 0.630 |
Why?
|
| Analysis of Variance | 8 | 2015 | 461 | 0.610 |
Why?
|
| Down-Regulation | 3 | 2016 | 142 | 0.610 |
Why?
|
| Dynorphins | 1 | 2017 | 6 | 0.600 |
Why?
|
| Receptors, Nicotinic | 2 | 2017 | 59 | 0.600 |
Why?
|
| Anxiety | 4 | 2016 | 188 | 0.600 |
Why?
|
| Fluoxetine | 4 | 2012 | 16 | 0.590 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2016 | 1 | 0.560 |
Why?
|
| Substantia Nigra | 2 | 2007 | 11 | 0.560 |
Why?
|
| Dopamine Antagonists | 1 | 2016 | 22 | 0.550 |
Why?
|
| Naltrexone | 1 | 2016 | 18 | 0.550 |
Why?
|
| Synapses | 2 | 2015 | 83 | 0.540 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 10 | 0.530 |
Why?
|
| Locomotion | 5 | 2016 | 31 | 0.530 |
Why?
|
| Up-Regulation | 1 | 2016 | 189 | 0.530 |
Why?
|
| Exocytosis | 3 | 2014 | 10 | 0.510 |
Why?
|
| Adaptation, Biological | 1 | 2014 | 8 | 0.500 |
Why?
|
| Feeding Behavior | 1 | 2016 | 161 | 0.500 |
Why?
|
| Membrane Glycoproteins | 6 | 2004 | 102 | 0.490 |
Why?
|
| Quinpirole | 6 | 2016 | 15 | 0.490 |
Why?
|
| Organ Culture Techniques | 5 | 2018 | 39 | 0.480 |
Why?
|
| Models, Neurological | 1 | 2015 | 117 | 0.480 |
Why?
|
| Biophysical Phenomena | 1 | 2014 | 6 | 0.480 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 43 | 0.470 |
Why?
|
| Blood Glucose | 1 | 2017 | 491 | 0.470 |
Why?
|
| Random Allocation | 6 | 2016 | 218 | 0.470 |
Why?
|
| Limbic System | 2 | 2013 | 13 | 0.460 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 1012 | 0.460 |
Why?
|
| Carrier Proteins | 6 | 2004 | 137 | 0.450 |
Why?
|
| Amphetamines | 2 | 2013 | 6 | 0.450 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 2015 | 17 | 0.450 |
Why?
|
| Sex Characteristics | 2 | 2016 | 169 | 0.440 |
Why?
|
| Kinetics | 5 | 2014 | 209 | 0.440 |
Why?
|
| Mesencephalon | 3 | 2009 | 18 | 0.430 |
Why?
|
| Depression | 2 | 2016 | 442 | 0.430 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 11 | 0.420 |
Why?
|
| Maternal Deprivation | 1 | 2012 | 3 | 0.410 |
Why?
|
| Benztropine | 1 | 2012 | 2 | 0.410 |
Why?
|
| Neurochemistry | 1 | 2011 | 3 | 0.390 |
Why?
|
| Neuropharmacology | 1 | 2011 | 3 | 0.380 |
Why?
|
| Macaca mulatta | 5 | 2020 | 285 | 0.380 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 272 | 0.380 |
Why?
|
| Mice, Inbred DBA | 3 | 2016 | 40 | 0.380 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 32 | 0.370 |
Why?
|
| Software | 1 | 2011 | 127 | 0.360 |
Why?
|
| Exploratory Behavior | 3 | 2017 | 30 | 0.360 |
Why?
|
| Blotting, Western | 4 | 2015 | 292 | 0.360 |
Why?
|
| Symporters | 3 | 2004 | 12 | 0.350 |
Why?
|
| Hyperkinesis | 1 | 2009 | 6 | 0.350 |
Why?
|
| Receptors, Serotonin | 1 | 2009 | 7 | 0.350 |
Why?
|
| Female | 17 | 2020 | 19859 | 0.350 |
Why?
|
| Brain Chemistry | 3 | 2008 | 29 | 0.330 |
Why?
|
| Obesity | 1 | 2016 | 1158 | 0.320 |
Why?
|
| Piperazines | 1 | 2008 | 54 | 0.310 |
Why?
|
| Age Factors | 3 | 2018 | 1187 | 0.310 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2016 | 94 | 0.310 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2007 | 4 | 0.290 |
Why?
|
| Macaca fascicularis | 4 | 2016 | 397 | 0.290 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 261 | 0.280 |
Why?
|
| Alcohol-Related Disorders | 2 | 2018 | 21 | 0.280 |
Why?
|
| Gene Knock-In Techniques | 2 | 2017 | 9 | 0.280 |
Why?
|
| Nitriles | 2 | 2016 | 23 | 0.260 |
Why?
|
| Basal Ganglia | 1 | 2005 | 15 | 0.260 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 131 | 0.260 |
Why?
|
| Species Specificity | 2 | 2016 | 87 | 0.260 |
Why?
|
| Sertraline | 2 | 2016 | 27 | 0.260 |
Why?
|
| Reaction Time | 2 | 2011 | 117 | 0.260 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 4 | 2015 | 9 | 0.260 |
Why?
|
| Chronic Disease | 2 | 2018 | 400 | 0.250 |
Why?
|
| Receptors, Histamine H1 | 1 | 2004 | 1 | 0.250 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2015 | 19 | 0.240 |
Why?
|
| Neural Inhibition | 1 | 2004 | 28 | 0.240 |
Why?
|
| Conditioning, Operant | 2 | 2015 | 88 | 0.240 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2005 | 16 | 0.240 |
Why?
|
| Drug Interactions | 3 | 2011 | 79 | 0.240 |
Why?
|
| Microelectrodes | 3 | 2016 | 16 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Phosphorylation | 2 | 2016 | 230 | 0.230 |
Why?
|
| Area Under Curve | 2 | 2017 | 91 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Dopamine Agonists | 6 | 2008 | 28 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Models, Animal | 4 | 2016 | 164 | 0.210 |
Why?
|
| Serotonin Uptake Inhibitors | 3 | 2016 | 37 | 0.210 |
Why?
|
| Extracellular Fluid | 3 | 2015 | 11 | 0.210 |
Why?
|
| Levodopa | 2 | 2016 | 14 | 0.200 |
Why?
|
| Antidepressive Agents | 3 | 2016 | 74 | 0.200 |
Why?
|
| Nonlinear Dynamics | 1 | 2001 | 51 | 0.200 |
Why?
|
| Injections, Intravenous | 3 | 2011 | 76 | 0.200 |
Why?
|
| Septal Nuclei | 2 | 2018 | 8 | 0.190 |
Why?
|
| Enzyme Inhibitors | 3 | 2017 | 164 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Receptors, Dopamine D3 | 3 | 2015 | 33 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 239 | 0.160 |
Why?
|
| Dopamine Agents | 2 | 2015 | 19 | 0.160 |
Why?
|
| KCNQ Potassium Channels | 1 | 2018 | 1 | 0.160 |
Why?
|
| Anxiety Disorders | 2 | 2016 | 77 | 0.160 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 127 | 0.150 |
Why?
|
| Tissue Culture Techniques | 2 | 2014 | 40 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 208 | 0.150 |
Why?
|
| Psychomotor Agitation | 2 | 2012 | 10 | 0.150 |
Why?
|
| Insulin | 2 | 2017 | 366 | 0.150 |
Why?
|
| Receptor, Insulin | 1 | 2017 | 10 | 0.140 |
Why?
|
| Pyridones | 1 | 2017 | 10 | 0.140 |
Why?
|
| Androstadienes | 1 | 2017 | 17 | 0.140 |
Why?
|
| Electrodes | 1 | 2017 | 19 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2017 | 28 | 0.140 |
Why?
|
| Triazoles | 1 | 2016 | 14 | 0.140 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2016 | 2 | 0.140 |
Why?
|
| Raclopride | 1 | 2016 | 8 | 0.140 |
Why?
|
| Benzeneacetamides | 1 | 2016 | 3 | 0.140 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2016 | 4 | 0.140 |
Why?
|
| Electrophysiology | 2 | 2006 | 70 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 2016 | 12 | 0.140 |
Why?
|
| Pruritus | 1 | 2016 | 47 | 0.140 |
Why?
|
| Fasting | 1 | 2017 | 95 | 0.140 |
Why?
|
| Phenmetrazine | 1 | 2016 | 4 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2016 | 66 | 0.140 |
Why?
|
| Serine | 1 | 2016 | 10 | 0.140 |
Why?
|
| Compulsive Behavior | 1 | 2016 | 4 | 0.140 |
Why?
|
| Indoles | 1 | 2016 | 56 | 0.140 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2016 | 24 | 0.140 |
Why?
|
| Humans | 7 | 2018 | 31836 | 0.140 |
Why?
|
| Amino Acids | 1 | 2016 | 46 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2015 | 181 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2015 | 36 | 0.130 |
Why?
|
| Macaca | 1 | 2015 | 24 | 0.130 |
Why?
|
| Stereotyped Behavior | 2 | 2013 | 13 | 0.130 |
Why?
|
| Phosphinic Acids | 1 | 2015 | 2 | 0.130 |
Why?
|
| Monoamine Oxidase | 1 | 2015 | 5 | 0.130 |
Why?
|
| RGS Proteins | 1 | 2015 | 18 | 0.130 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Propanolamines | 1 | 2015 | 11 | 0.130 |
Why?
|
| Interneurons | 1 | 2015 | 22 | 0.130 |
Why?
|
| Animals, Newborn | 1 | 2015 | 114 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 181 | 0.130 |
Why?
|
| Artifacts | 1 | 2015 | 39 | 0.130 |
Why?
|
| Acetylcholine | 1 | 2015 | 47 | 0.130 |
Why?
|
| Pyrethrins | 1 | 2015 | 12 | 0.120 |
Why?
|
| Mecamylamine | 1 | 2014 | 11 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2015 | 70 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 99 | 0.120 |
Why?
|
| Nicotinic Antagonists | 1 | 2014 | 17 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2015 | 75 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 75 | 0.120 |
Why?
|
| Biological Transport | 1 | 2014 | 69 | 0.120 |
Why?
|
| Amygdala | 1 | 2015 | 60 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Fenfluramine | 1 | 2014 | 4 | 0.120 |
Why?
|
| Serotonin Agents | 1 | 2014 | 5 | 0.120 |
Why?
|
| Pain | 1 | 2016 | 287 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2014 | 293 | 0.120 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 36 | 0.120 |
Why?
|
| Body Composition | 1 | 2016 | 388 | 0.120 |
Why?
|
| Stimulation, Chemical | 1 | 2013 | 13 | 0.120 |
Why?
|
| Desipramine | 2 | 2004 | 5 | 0.120 |
Why?
|
| Mice, Mutant Strains | 3 | 2009 | 52 | 0.110 |
Why?
|
| Receptors, Dopamine | 1 | 2013 | 20 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 231 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2017 | 461 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2016 | 895 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 345 | 0.110 |
Why?
|
| Chromatography | 1 | 2012 | 4 | 0.100 |
Why?
|
| Gene Deletion | 2 | 2004 | 66 | 0.100 |
Why?
|
| Nomifensine | 1 | 2012 | 3 | 0.100 |
Why?
|
| Spatial Behavior | 1 | 2012 | 11 | 0.100 |
Why?
|
| Bupropion | 1 | 2012 | 5 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 186 | 0.100 |
Why?
|
| Calcium | 1 | 2013 | 304 | 0.100 |
Why?
|
| Anesthetics, General | 1 | 2011 | 1 | 0.100 |
Why?
|
| Potentiometry | 1 | 2010 | 1 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 48 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 370 | 0.090 |
Why?
|
| Infusions, Parenteral | 1 | 2010 | 66 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2007 | 22 | 0.090 |
Why?
|
| Benzoxazoles | 1 | 2009 | 1 | 0.090 |
Why?
|
| Receptors, Neuropeptide | 1 | 2009 | 3 | 0.090 |
Why?
|
| Naphthyridines | 1 | 2009 | 4 | 0.090 |
Why?
|
| Urea | 1 | 2009 | 37 | 0.090 |
Why?
|
| Ethylnitrosourea | 1 | 2009 | 1 | 0.090 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2009 | 2 | 0.090 |
Why?
|
| Matched-Pair Analysis | 1 | 2009 | 12 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 44 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2009 | 57 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 85 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2008 | 5 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 21 | 0.080 |
Why?
|
| Volatilization | 1 | 2007 | 5 | 0.070 |
Why?
|
| Reinforcement Schedule | 1 | 2007 | 57 | 0.070 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 27 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 57 | 0.070 |
Why?
|
| Tetrabenazine | 1 | 2006 | 3 | 0.070 |
Why?
|
| Tetrodotoxin | 1 | 2006 | 11 | 0.070 |
Why?
|
| Electrodes, Implanted | 1 | 2006 | 42 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 47 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2006 | 55 | 0.070 |
Why?
|
| Anesthesia | 1 | 2006 | 63 | 0.070 |
Why?
|
| Biogenic Monoamines | 1 | 2005 | 4 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2007 | 173 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 109 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2005 | 184 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 17 | 0.060 |
Why?
|
| Biological Assay | 1 | 2004 | 19 | 0.060 |
Why?
|
| Phenethylamines | 1 | 2004 | 2 | 0.060 |
Why?
|
| Patch-Clamp Techniques | 2 | 2015 | 75 | 0.060 |
Why?
|
| Haplorhini | 1 | 2003 | 66 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 835 | 0.060 |
Why?
|
| Algorithms | 1 | 2006 | 495 | 0.050 |
Why?
|
| Protein Binding | 2 | 2015 | 201 | 0.050 |
Why?
|
| Synaptic Membranes | 1 | 2002 | 3 | 0.050 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2002 | 3 | 0.050 |
Why?
|
| Membrane Transport Modulators | 1 | 2002 | 4 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1514 | 0.050 |
Why?
|
| Neural Pathways | 1 | 2001 | 94 | 0.050 |
Why?
|
| Homozygote | 1 | 2000 | 58 | 0.040 |
Why?
|
| Alcohol Deterrents | 1 | 2018 | 2 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2018 | 78 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2018 | 158 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 2011 | 33 | 0.040 |
Why?
|
| Diet | 1 | 2020 | 385 | 0.040 |
Why?
|
| Nicotinic Agonists | 1 | 2017 | 39 | 0.040 |
Why?
|
| Tropanes | 1 | 2016 | 9 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2016 | 133 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 2016 | 15 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 284 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 107 | 0.030 |
Why?
|
| Tritium | 1 | 2015 | 14 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 9 | 0.030 |
Why?
|
| Maze Learning | 1 | 2015 | 13 | 0.030 |
Why?
|
| Synaptosomes | 1 | 2015 | 17 | 0.030 |
Why?
|
| Insecticides | 1 | 2015 | 20 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2015 | 96 | 0.030 |
Why?
|
| Nicotine | 1 | 2017 | 171 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2015 | 19 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 208 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 248 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2015 | 96 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2015 | 54 | 0.030 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2014 | 5 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 184 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 27 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 566 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 77 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2014 | 81 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 306 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 334 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 508 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 771 | 0.030 |
Why?
|
| Action Potentials | 1 | 2014 | 177 | 0.030 |
Why?
|
| Attention | 1 | 2013 | 83 | 0.030 |
Why?
|
| Learning | 1 | 2013 | 78 | 0.030 |
Why?
|
| Sleep | 1 | 2013 | 92 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 9327 | 0.030 |
Why?
|
| Glucose | 1 | 2013 | 173 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 10288 | 0.030 |
Why?
|
| Memory | 1 | 2013 | 190 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 487 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 11824 | 0.020 |
Why?
|
| Phenotype | 2 | 2006 | 635 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1527 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1323 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 15 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 8 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2425 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 37 | 0.020 |
Why?
|
| Histones | 1 | 2008 | 53 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 3294 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 3511 | 0.020 |
Why?
|
| Environment | 1 | 2006 | 53 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2005 | 59 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 80 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 12 | 0.020 |
Why?
|
| Wakefulness | 1 | 2004 | 25 | 0.020 |
Why?
|
| Phenanthridines | 1 | 2002 | 1 | 0.010 |
Why?
|
| Prolactin | 1 | 2002 | 9 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 21 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2002 | 9 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 35 | 0.010 |
Why?
|
| Apomorphine | 1 | 2001 | 1 | 0.010 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2001 | 3 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 2001 | 11 | 0.010 |
Why?
|
| Benzazepines | 1 | 2001 | 21 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 132 | 0.010 |
Why?
|